

Supplementary

Table S1 Conversion therapy protocols

Conversion therapy protocols	Patients, n (%)
Sintilimab + lenvatinib	50 (79.4)
Pembrolizumab + lenvatinib	4 (6.3)
Tislelizumab + lenvatinib	3 (4.8)
Toripalimab + lenvatinib	3 (4.8)
Camrelizumab + apatinib	1 (1.6)
Toripalimab + apatinib	1 (1.6)
Toripalimab + sorafenib	1 (1.6)